New

Symptom Improvement Seen With Interpersonal Psychotherapy, Sertraline in Postpartum Women

Investigators examined the efficacy of sertraline and interpersonal psychotherapy vs pill placebo over 12 weeks in woman with postpartum depression.

New

FDA to Review Lumateperone for Treatment of Schizophrenia

Lumateperone and follow-on compounds are also being evaluated for bipolar depression, behavioral disturbance associated with dementia, sleep disturbances associated with neuropsychiatric disorders, and other neuropsychiatric conditions including major depressive disorder and autism.

New

Polygenic Risk Scores May Predict Antipsychotic Efficacy in Schizophrenia

The use of a polygenic risk score for schizophrenia can effectively predict an antipsychotic treatment response after a first episode of psychosis.

New

Can Examining Marginalization Identify Gaps in Medical or Nutritional Care?

Healthcare interventions should assess the multiple layers of a person’s life, rather than simply classifying marginalized groups as vulnerable.